Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NNI-370
- Development stage
- Preclinical
- Lead developer
- Neuronascent
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NNI-370 is a novel small molecule therapeutic candidate developed by Neuronascent for the treatment of Parkinson's disease and other neurodegenerative conditions. It belongs to a proprietary family of compounds designed to stimulate neurogenesis, specifically by promoting the growth of new neurons from ventral midbrain stem cells. Additionally, NNI-370 exhibits neuroprotective properties by inhibiting the death of dopaminergic neurons, which are characteristically lost in Parkinson's disease. The program is currently in the IND-enabling phase, aiming to provide a disease-modifying approach that both restores lost neuronal populations and preserves existing ones.
- Other names
- NNI-370NNI370NNI 370
Beyond the preview
Go deeper on NNI-370.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NNI-370.